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Abstract Metalloproteinases (MMP)-2 and MMP-9 play a
role in smooth muscle cell (SMC) migration from the media
to the intima following arterial injury. Intravenous administra-
tion of adenovirus encoding tissue inhibitor of metalloprotei-
nase-1 (TIMP-1) into balloon-injured rat arteries (3U1011 viral
particles/rat ; n=7) resulted in a transient expression of TIMP-
1 and a signi¢cant inhibition of neointima thickening within 16
days (V40% vs. control ; P=0.012). Three days after injury,
the number of intimal SMCs was decreased by V98% in
TIMP-1-treated rats. However, no alteration was seen in inti-
mal SMC proliferation after 13 days of injury. Therefore, our
results show that systemic gene transfer of TIMP-1 is a prom-
ising approach in early restenosis treatment.
4 2002 Federation of European Biochemical Societies. Pub-
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1. Introduction
Studies on animal models and in vitro systems have indi-
cated that vascular smooth muscle cell (SMC) migration from
the media to the intima and proliferation are important in the
development of neointima [1]. Several growth and chemotactic
factors as well as plasminogen/plasmin systems and matrix
metalloproteinases (MMPs) have been reported to play a
role in this phenomenon [2^6].
MMPs are a family of enzymes which together degrade all
components of extracellular matrix [7]. The activity of MMPs
is tightly controlled by endogenous speci¢c inhibitors, the tis-
sue inhibitors of matrix metalloproteinases (TIMPs), a family
of four members [7,8]. Imbalance of MMP activity over
TIMPs in the vasculature promotes migration and prolifera-
tion of vascular SMCs [7]. Thus, expression of gelatinase A
(MMP-2) and gelatinase B (MMP-9), both produced by a
variety of cells including vascular cells, is enhanced in the
aorta of atherogenic diet-fed rabbits [9] and in perivascular
electric injury in the mouse [10], rat [4,11] and pig [12] models
of carotid angioplasty. Therefore, inhibition of MMP activity
by pharmacological compounds or by gene transfer of TIMPs
could arrest SMC migration and neointima formation. In-
deed, local overexpression of TIMP-1 or TIMP-2, using ad-
enoviral vectors, has been reported to inhibit neointima for-
mation in the rat model of angioplasty restenosis and in an in
vitro human model of vein graft [12]. Similarly, local adeno-
virus-mediated overexpression of TIMP-3 at the luminal sur-
face of human and pig saphenous vein promotes apoptosis in
the neointima and medial layer leading to a signi¢cant reduc-
tion of neointima formation [13]. However, local delivery of
genes to sites of neointima formation is problematic due to
the local di⁄culties of using infusion devices to deliver genes
to the vessel wall. Therefore, increasing appropriate gene
products in plasma following intravenous adenovirus injection
could be a promising new approach to the treatment of vas-
cular diseases. Indeed, Carmeliet and colleagues [14] have re-
ported that systemic overexpression of tissue-type plasmino-
gen activator, using adenovirus vector, augments thrombolysis
in tissue-type plasminogen activator-de¢cient and plasmino-
gen activator inhibitor-1-overexpressing mice. In this study,
we show, for the ¢rst time, a signi¢cant inhibition of new
intima thickening in balloon-injured rat carotid artery by in-
creasing the plasma TIMP-1 level through intravenous admin-
istration of either adenovirus TIMP-1 vector or recombinant
human TIMP-1 protein.
2. Materials and methods
2.1. Generation of the recombinant adenovirus
Recombinant vectors Ad.RSV.LGal and Ad.RSV.TIMP-1 were
constructed as described earlier [15]. High-titer stocks of viral particles
(vp) (5.8U1012, 1.2U1012) were produced in 293 cells for rAd.RSV.-
TIMP-1 and rAd.RSV.LGal respectively, and were puri¢ed on CsCl
gradients.
2.2. Rat model of balloon injury
The rat carotid artery balloon injury model was based on a model
described by Clowes et al. [16]. Adult male Sprague^Dawley rats
weighing 400^600 g were subjected to a distending, de-endothelializing
injury with an in£ated 2F Fogarty embolectomy catheter inserted
through the external carotid artery.
2.3. Local delivery of adenoviruses
On day 0, the left injured segments of arteries of eight rats were
incubated in the presence of rAd.RSV.TIMP-1 (1U1011 vp) and the
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right injured segments of arteries of the same eight rats were incuba-
ted in the presence of rAd.RSV.LGal (1U1011 vp) in a total volume of
100 Wl saline for 15 min according to the previous described protocol
[17]. On day 14, the rats were killed with an intraperitoneal injection
of pentobarbital (100 mg/kg). The balloon-injured segments of the
arteries from the proximal edge of the omohyoid muscle to the carotid
bifurcation were perfused with saline and dissected. The tissues were
then ¢xed with 100% methanol and embedded in para⁄n. Histological
images of 4 Wm cross-sections from the center of the injured segment
were stained with hematoxylin-eosin or elastic-trichrome and used to
determine the intimal, medial, and luminal areas by quantitative mor-
phometric analysis with a computerized sketching program
(MACMEASURE version 1.9). Three sections from each artery
were evaluated by an investigator who was blinded to the identities
of the treatment groups. The experimental protocol was approved by
the Institutional Animal Care and Use Committee of St. Elizabeth’s
Medical Center and complied with the National Institutes of Health
Guide for the Care and Use of Laboratory Animals.
2.4. Intravenous administration of adenoviruses
On day 0, a group of seven rats received an injection in the tail vein
with rAd.RSV.TIMP-1 (3U1011 vp) and blood was drawn for plasma
TIMP-1 evaluation. On day 3, a carotid balloon injury was performed
on all animals and blood was drawn. On days 6 and 12, only blood
was drawn and ¢nally, on day 16, blood was collected and vessels
were harvested for histology analysis.
2.5. Vascular smooth muscle cell proliferation in systemic
rAd.RSV.TIMP-1- or rAd.RSV.LGal-infused rats
First, the rats were treated with rAd.RSV.TIMP-1 (3U1011 vp;
n=3) or rAd.RSV.LGal (3U1011 vp; n=3) on day 0. Second, the
rat carotid arteries were balloon-injured on day 3. Third, in order
to label all cells entering S-phase during the last 24 h before sacri¢cing
rats on day 13 after balloon injury, subcutaneous injections (25 mg/kg
body weight) of bromodeoxyuridine (Boehringer Mannheim) were
performed at 19, 9 and 1 h before death by pentobarbital injection
as described earlier [11]. The rats were then killed and the vessels were
¢xed and immersed in 4% paraformaldehyde for 1 h according to
Bendeck et al. [11]. Thereafter, 5 mm lengths of the carotid arteries
were cut and embedded in para⁄n, and histological cross-sections
were made for the evaluation of intimal SMC proliferation as de-
scribed [18].
2.6. Vascular smooth muscle cell migration in systemic
rAd.RSV.TIMP-1- or rAd.RSV.LGal-infused rats
First, rats were injected on day 0 with rAd.RSV.TIMP-1 (3U1011
vp; n=4) or rAd.RSV.LGal (3U1011 vp; n=4). Second, the rat ca-
rotid arteries were balloon-injured on day 3. Third, 3 days after bal-
loon injury, a 1 cm length of vessel was excised from the middle of the
¢xed common carotid and used to determine SMC migration as de-
scribed earlier [19]. Brie£y, migration was determined by staining the
nuclei of intimal cells using an antibody against histone H1 (mAb
1276, Chemicon International) and by counting the number of cells
in the intima.
2.7. SDS^PAGE zymography
Proteins were extracted from control and injured rat carotid artery
as described by Olsen et al. [20]. SDS^polyacrylamide (Millipore,
France) gel containing 1 mg/ml gelatin (Bio-Rad) was used to visual-
ize gelatinolytic activity for MMP-2 and MMP-9 [21]. Clear bands
indicated the presence of proteolytic activity. To analyze the activity
of human TIMP-1 against arterial rat MMPs, a similar gel was em-
ployed and incubated with recombinant human TIMP-1 (a kind gift
from G. Murphy).
2.8. Quanti¢cation of human TIMP-1 in rat plasma or culture media by
the ELISA procedure
Human TIMP-1 in rat plasma or rat carotid culture media (follow-
ing rAd.RSV.TIMP-1 transfection) was quantitated with a sandwich
ELISA kit (Amersham, France), containing two monoclonal antibod-
ies speci¢c to human TIMP-1 antigen.
2.9. Statistical analysis
The intima/media ratio was compared between groups by Student’s
t-test.
3. Results
Infusion of rats with rAd.RSV.TIMP-1 at 3U1011 vp/rat
resulted in a transient expression of TIMP-1 (Fig. 1). On
day 6 after injection, plasma TIMP-1 levels reached V100Q
12 ng/ml and they decreased to V8Q 0.9 ng/ml by 12 days.
The endogenous plasma TIMP-1 could not be evaluated
due to the absence of a speci¢c murine ELISA kit. This ad-
ministration procedure of rAd.RSV.TIMP-1 (3U1011 vp/rat)
resulted in a signi¢cant inhibition of neointima thickening in
16 days (intima/media (I/M) ratio = 0.56Q 0.45; P=0.012 vs.
control) (Figs. 2B and 3). In addition, kinetic analysis of in
vivo TIMP-1 production following local delivery of rAd.-
RSV.TIMP-1 (1U1011 vp/rat) on balloon-injured arteries of
three animals was performed. The result showed that the plas-
ma TIMP-1 level was merely detectable while the TIMP-1
concentration in homogenized transfected artery indicated a
maximum concentration of V3Q 0.7 ng/106 intimal SMCs
following 6 days of transfection (not shown). In addition,
local delivery of rAd.RSV.TIMP-1 into rat balloon-injured
left carotid resulted in a signi¢cant reduction of the I/M ratio
after 14 days of transfection as compared to the balloon-in-
jured right carotid of the same animal transfected with
rAd.RSV.LGal. The I/M was 1.17Q 0.20 for the control and
0.54Q 0.19 for the rAd.RSV.TIMP-1-treated rats (P=0.038
vs. the control group). This inhibition represents V49% vs.
the control (Fig. 2A). Furthermore, intravenous rAd.RSV.-
TIMP-1 administration (n=3) was found to reduce intimal
SMC migration by day 3 after injury. The number of intimal
SMCs was decreased from 114Q 21 cells/mm2 in rAd.RSV.-
LGal-treated rats to 2.2Q 2 cells/mm2 in rAd.RSV.TIMP-1-
treated rats (P=0.005) (Fig. 4A). However, no signi¢cant
alteration in intimal SMC proliferation occurred at 13 days
after injury between the control and rAd.RSV.TIMP-1-treated
rats (14.3 Q 4% for the control group (n=4) and 17Q4% for
the rAd.RSV.TIMP-1-treated rats (n=4)) (Fig. 4B). It is most
likely that these e¡ects were due to MMP inhibition since
zymography study showed that human TIMP-1 was able to
inhibit the activity of rat MMPs (Fig. 5).
Fig. 1. Kinetic expression of human TIMP-1 in rat plasma follow-
ing intravenous injection of rAd.RSV.TIMP-1 adenovirus. Adult
male Sprague^Dawley rats (n=7) received an injection of rAd.RSV.-
TIMP-1 (3U1011 vp) in the tail vein. Blood was drawn and plasma
TIMP-1 evaluated using a sandwich ELISA kit. Values are mean-
s Q S.E.M.
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4. Discussion
Increased matrix-degrading MMP activity has been re-
ported in several arterial pathologies such as intimal hyper-
plasia after angioplasty or vein graft [22]. Vascular SMC mi-
gration from the media and proliferation in the neointima are
events believed to be the consequence, at least in part, of the
action of MMPs. Indeed, enhanced SMC migration and neo-
intima proliferation have been reported when rat SMCs are
transfected with MMP-9 and seeded into the luminal surface
Fig. 2. Histological analysis of balloon-injured rat carotid arteries.
Following rAd.RSV.LGal (control) or rAd.RSV.TIMP-1 treatment,
adult rats were subjected to a distending, de-endothelializing injury.
A: Local delivery of adenoviruses was performed on day 0. The left
and right injured segments of arteries of eight rats were incubated
in the presence of rAd.RSV.TIMP-1 (1U1011 vp) (left) or rAd.RSV.-
LGal (1U1011 vp) (right). On day 14, rats were killed and the inti-
mal, medial, and luminal areas were quantitated. B: Intravenous ad-
ministration of adenoviruses was performed on 14 rats divided into
two groups (n=7 each). On day 0, each group received an injection
in the tail vein of either rAd.RSV.TIMP-1 (3U1011 vp) or rAd.RSV.-
LGal (3U1011 vp) (control) and blood was drawn for plasma
TIMP-1 evaluation. On day 3, a carotid balloon injury was per-
formed on all animals and blood was drawn. On days 6 and 12,
only blood was drawn and ¢nally, on day 16, blood was collected
and vessels were harvested for histology analysis. Values are
meansQS.D.
6
Fig. 3. The balloon-injured segments of the arteries were perfused with saline and dissected. The tissues were then ¢xed and embedded in paraf-
¢n. Histological images of 4 Wm cross-sections from the center of the injured segment were used to determine the intimal, medial, and luminal
areas by quantitative morphometric analysis. A: rAd.RSV.LGal-treated rats (control). B: rAd.RSV.TIMP-1-treated rats.
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of denuded artery [23]. Conversely, a de¢ciency of TIMP-1 in
mice signi¢cantly enhances neointima formation following in-
jury of the femoral artery, con¢rming the role of MMPs with
respect to SMC migration [24]. In addition, inhibition of
MMP by adenovirus-mediated overexpression of TIMP-1
has a bene¢cial e¡ect on aneurysmal degeneration [25] and
neointimal formation in several models [26]. However, these
latter studies concerned local delivery of the TIMP-1 gene.
Although these approaches clarify the role of TIMP-1 in the
inhibition of neointima formation, they are not convenient for
therapeutic treatment due to the local di⁄culties of using in-
fusion devices to deliver genes to the vessel wall.
In this study, we evaluated the impact of elevated plasma
TIMP-1 on neointima formation, following intravenous ad-
ministration of rAd.RSV.TIMP-1 in rat injured carotid. In
this approach, the liver is utilized as a source of production
of TIMP-1 protein. A single injection of adenoviral vector
(3U1011 vp/rat) signi¢cantly reduced neointima formation
by approximately 40% after 16 days of balloon injury. The
highest level of plasma TIMP-1 following adenovirus admin-
istration was approximately 100 ng/ml. Nevertheless, a com-
parison of this concentration with basic endogenous murine
plasma TIMP-1 cannot be performed since, to the best of
our knowledge, there is no ELISA kit available for murine
TIMP-1 quanti¢cation. Similarly, local TIMP-1 delivery us-
ing rAd.RSV.TIMP-1 transiently increased TIMP-1 to reach
V3 ng/106 intimal SMCs and reduced neointima formation
by V48% after 14 days of balloon injury. This bene¢cial
e¡ect can be attributed to the local expression of TIMP-1.
Plasma TIMP-1-derived local transfection is hardly detectable
(data not shown) which supports the hypothesis that human
TIMP-1 concentration in the microenvironment is su⁄cient to
counterbalance the activity of local MMPs. In addition,
rAd.RSV.TIMP-1 inhibited SMC migration from the media
to the intima after 3 days of balloon injury. The cell migration
phenomenon is mediated, at least in part, by the action of
MMPs such as MMP-2 and MMP-9. Inhibition of the activity
of these enzymes using human TIMP-1 blocked SMC migra-
tion. Indeed, human TIMP-1 was found to inhibit rat MMPs
as shown by a zymography study (Fig. 5). However, there was
no e¡ect on SMC proliferation with rAd.RSV.TIMP-1 at 13
days after balloon injury indicating that a di¡erent process
was involved in this phenomenon.
It should be noted that GM6001, a non-speci¢c synthetic
MMP inhibitor, has been shown to impair SMC migration
and to reduce the lesion size following continuous treatment
for up to 10 days after a rat carotid artery had been injured
Fig. 4. A: Vascular SMC migration. Six rats were divided into two
groups. On day 0, the ¢rst group (n=3) received an injection in the
tail vein with rAd.RSV.LGal (control group) and the second group
(n=3) received an injection with rAd.RSV.TIMP-1. On day 3, the
left and right arteries of both groups were injured. On day 6 (or
day 3 after balloon injury), cell migration was determined by count-
ing the number of SMCs in the intima, expressed per unit of surface
area. Data are meanQS.D. B: Intimal SMC proliferation. Thirteen
days after balloon injury (which correspond to 16 days after adeno-
virus injection), rats (n=3 for rAd.RSV.LGal and n=3 for
rAd.RSV.TIMP-1) were used to evaluate the percentage of intimal
SMC proliferation. Data are meanQS.D.
Fig. 5. Zymography. Proteins (10 Wg) from control or balloon-injured rat carotid artery for 6 days were electrophoresed in 10% SDS^polyacryl-
amide gel containing 1 mg/ml gelatin. Clear bands indicate the presence of proteolytic activity. To analyze the activity of human TIMP-1
against arterial rat MMPs, two similar gels were made and incubated with recombinant human TIMP-1 at 5 and 100 ng/ml.
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by balloon catheter [11]. In our study, systemic overexpression
of human TIMP-1, using rAd.RSV.TIMP-1 vector, was e⁄ca-
cious in the rat carotid injury model for up to 16 days sug-
gesting that TIMP-1 is functionally di¡erent from GM6001.
For example, inhibition of multiple MMPs with synthetic in-
hibitors might lead to inactivation of stromelysin-3 (MMP-11)
which has been reported to accelerate neointima formation
after vascular injury in mice [5].
Circulating TIMP-1 could exercise a relatively prolonged
protection against MMP-mediated degradation of speci¢c
extracellular molecules. This latter phenomenon is now well
established as being responsible for SMC migration [23,24].
However, neither the available synthetic MMP inhibitors nor
TIMP-1 a¡ect SMC proliferation. This is a major drawback,
since it is unlikely that neointima thickening could be reduced
without blocking of the SMC proliferation. With this partic-
ular gene therapy approach, we hypothesize that a combina-
tion of Ad.TIMP-1 and Ad.TIMP-3 might give a better result,
since TIMP-3 has been shown to promote apoptosis in the
neointima and medial layer, leading to a signi¢cant reduction
of neointima formation [13].
In conclusion, local vascular transfer of several genes has
produced bene¢cial e¡ects in the treatment of experimental
restenosis. Nevertheless, intravenous injection of adenovi-
ruses, a simple way to overexpress genes, could give a similar
result. Unfortunately, several problems remain to be solved
before gene transfer can be applied to clinical medicine and
notably the use of a new generation of vectors, allowing long
duration expression of MMP inhibitors.
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